Curis LifesciencesNSE:CURIS -0.49%19 Net Margin % is 11.50% as of Mar. 2026, which is 6% below its 10-year median of 12.24. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 954 Drug Manufacturers companies, Curis Lifesciences ranks better than 68.66% on this metric.
The historical rank and industry rank for Curis Lifesciences's Net Margin % or its related term are showing as below:
NSE:CURIS'
s Net Margin % Range Over the Past 10 Years
Min: 5.29 Med: 12.24 Max: 13.69
Current: 11.5
NSE:CURIS's Net Margin % is ranked better than 68.66% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.695
vs NSE:CURIS: 11.50
Curis Lifesciences (NSE:CURIS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Curis Lifesciences Net Margin % Related Terms
Curis Lifesciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Net Margin % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Net Margin %
5.29
13.69
12.98
11.50
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Net Margin %
5.29
13.69
12.98
11.50
NSE:CURIS vs ZTS, UTHR: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Net Margin % of 11.50% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Curis Lifesciences and its competitors. This is near median its historical median of 12.24. Over the past decade, Curis Lifesciences' Net Margin % has ranged from 5.29 to 13.69. According to the industry distribution chart, Curis Lifesciences ranks #299 out of 954 companies in the Drug Manufacturers industry, placing it in the top 31.3%.
Is Curis Lifesciences' Net Margin % too high?
Curis Lifesciences' current Net Margin % of 11.50% is near median its 10-year median of 12.24. Over the past 10 years, this metric has ranged from a low of 5.29 to a high of 13.69. The Drug Manufacturers industry median Net Margin % is 5.70. Curis Lifesciences' value of 11.50% is 101.9% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #299 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #299 out of 954 companies for Net Margin %. This puts Curis Lifesciences in the upper half of its industry. The industry median Net Margin % is 5.70. Curis Lifesciences' value of 11.50% is 101.9% above this benchmark. Historically, Curis Lifesciences' own Net Margin % has ranged from 5.29 to 13.69 over the past decade. While the company's 10-year median is 12.24 vs. the industry median of 5.70, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.70, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Net Margin % of 11.50% is 101.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Net Margin % is 11.50%, which is near median its own 10-year median of 12.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Net Margin % of 11.50%. The current Net Margin % is 11.50%, which is near median its 10-year median of 12.24 and 101.9% above the Drug Manufacturers industry median of 5.70. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Net Margin % is 11.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 